EN
TR
Entecavir induced gynecomastia- Triggering factor or coincidence?
Abstract
Entecavir is an important nucleoside analogue that plays a pivotal role in the treatment of Hepatitis B infection. In this case report, it was aimed to present a case regarding bilateral gynecomastia and mastodonia while receiving entecavir treatment.
Keywords
References
- 1. Karagoz E, Selek MB, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infez Med. 2016;24(4):287-292.
- 2. Karagöz E, Tanoğlu A. Importance of serum hepatitis B surface antigen and hepatitis e antigen quantification among patients with chronic hepatitis B. Turk J Gastroenterol. 2015;26:357.
- 3. Nikolopoulou GB, Tzoutzas I, Tsakris A, Maltezou HC. Hepatitis B in healthcare personnel: an update on the global landscape. Viruses. 2023;15(12):2454. doi: 10.3390/v15122454
- 4. Karagoz E, Ulcay A, Tanoglu A, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320-1324.
- 5. Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41(3):310-319.
- 6. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779-795. doi: 10.1517/14740338.2012.712109
- 7. Berger O, Landau Z, Talisman R. Gynecomastia: a systematic review of pharmacological treatments. Front Pediatr. 2022;10:978311. doi: 10.3389/fped.2022.978311
- 8. Henriquez-Camacho C, Hijas-Gomez AI, Risco Risco C, Ruiz Lapuente MA, Escudero-Sanchez R, Cuerda VM. Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis. Viruses. 2023;15(11):2241. doi: 10.3390/v15112241
Details
Primary Language
English
Subjects
Gastroenterology and Hepatology
Journal Section
Letter to Editor
Publication Date
April 30, 2024
Submission Date
March 31, 2024
Acceptance Date
April 25, 2024
Published in Issue
Year 2024 Volume: 5 Number: 2
APA
Tanoğlu, A., & Yeniçeri, M. (2024). Entecavir induced gynecomastia- Triggering factor or coincidence? Journal of Medicine and Palliative Care, 5(2), 147-148. https://doi.org/10.47582/jompac.1462353
AMA
1.Tanoğlu A, Yeniçeri M. Entecavir induced gynecomastia- Triggering factor or coincidence? J Med Palliat Care / JOMPAC / jompac. 2024;5(2):147-148. doi:10.47582/jompac.1462353
Chicago
Tanoğlu, Alpaslan, and Murat Yeniçeri. 2024. “Entecavir Induced Gynecomastia- Triggering Factor or Coincidence?”. Journal of Medicine and Palliative Care 5 (2): 147-48. https://doi.org/10.47582/jompac.1462353.
EndNote
Tanoğlu A, Yeniçeri M (April 1, 2024) Entecavir induced gynecomastia- Triggering factor or coincidence? Journal of Medicine and Palliative Care 5 2 147–148.
IEEE
[1]A. Tanoğlu and M. Yeniçeri, “Entecavir induced gynecomastia- Triggering factor or coincidence?”, J Med Palliat Care / JOMPAC / jompac, vol. 5, no. 2, pp. 147–148, Apr. 2024, doi: 10.47582/jompac.1462353.
ISNAD
Tanoğlu, Alpaslan - Yeniçeri, Murat. “Entecavir Induced Gynecomastia- Triggering Factor or Coincidence?”. Journal of Medicine and Palliative Care 5/2 (April 1, 2024): 147-148. https://doi.org/10.47582/jompac.1462353.
JAMA
1.Tanoğlu A, Yeniçeri M. Entecavir induced gynecomastia- Triggering factor or coincidence? J Med Palliat Care / JOMPAC / jompac. 2024;5:147–148.
MLA
Tanoğlu, Alpaslan, and Murat Yeniçeri. “Entecavir Induced Gynecomastia- Triggering Factor or Coincidence?”. Journal of Medicine and Palliative Care, vol. 5, no. 2, Apr. 2024, pp. 147-8, doi:10.47582/jompac.1462353.
Vancouver
1.Alpaslan Tanoğlu, Murat Yeniçeri. Entecavir induced gynecomastia- Triggering factor or coincidence? J Med Palliat Care / JOMPAC / jompac. 2024 Apr. 1;5(2):147-8. doi:10.47582/jompac.1462353
